nach oben

Erschienen in:

10.06.2016 | Original Article

RETRACTED ARTICLE: Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia

verfasst von: Takashi Nojiri, Hiroshi Hosoda, Masahiro Zenitani, Takeshi Tokudome, Toru Kimura, Koichi Miura, Mikiya Miyazato, Meinoshin Okumura, Kenji Kangawa

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Granulocytopenia is the major toxicity associated with cisplatin treatment. Atrial natriuretic peptide (ANP) is a cardiac hormone used clinically for the treatment of acute heart failure in Japan. ANP exerts a wide range of protective effects on various organs, including the heart, blood vessels, lungs, and kidneys. This study’s objective was to investigate the protective effects of ANP on cisplatin-induced granulocytopenia in mice.

Methods

The mice were divided into two groups: cisplatin with vehicle and cisplatin with ANP. ANP (1.5 μg/kg/min via osmotic pump, subcutaneously) or vehicle administration was started 1 day before cisplatin injection until the mice were killed. At 0, 2, 4, 8, and 14 days after cisplatin injection (16 mg/kg, intraperitoneally as a single dose), the white blood cell, red blood cell, and platelet counts were measured in the peripheral blood in both groups. The numbers of total and live cells and colony-forming unit-granulocyte–macrophage (CFU-GM) colonies in the bone marrow of the mice were also examined. In addition, at 0, 0.5, 1, and 2 days after cisplatin injection, serum granulocyte colony-stimulating factor (G-CSF) levels were measured.

Results

ANP significantly attenuated the white blood cell count decrease in the peripheral blood 2 and 4 days after cisplatin injection. ANP also attenuated the decrease in the number of live cells and CFU-GM colonies in bone marrow 2, 4, and 8 days after cisplatin injection. ANP significantly increased serum G-CSF levels 1 day after cisplatin injection.

Conclusions

ANP has protective effects in cisplatin-induced granulocytopenia, with increased G-CSF production.

Montoya L (2007) Managing hematologic toxicities in the oncology patient. J Infus Nurs 30:168–172CrossRefPubMed

Shelton BK (2003) Evidence-based care for the neutropenic patient with leukemia. Semin Oncol Nurs 19:133–141CrossRefPubMed

Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791–2808CrossRefPubMed

Franzke A (2006) The role of G-CSF in adaptive immunity. Cytokine Growth Factor Rev 17:235–244CrossRefPubMed

Panopoulos AD, Watowich SS (2008) Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine 42:277–288CrossRefPubMedPubMedCentral

Xu S, Höglund M, Venge P (1996) The effect of granulocyte colony-stimulating factor (G-CSF) on the degranulation of secondary granule proteins from human neutrophils in vivo may be indirect. Br J Haematol 93:558–568CrossRefPubMed

Bennett CL, Djulbegovic B, Norris LB, Armitage JO (2013) Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 368:1131–1139CrossRefPubMedPubMedCentral

Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K, Kangawa K (2009) Natriuretic peptide signaling via guanylyl cyclase (GC)-A: an endogenous protective mechanism of the heart. Curr Cardiol Rev 5:45–51CrossRefPubMedPubMedCentral

Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M (2008) Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 29:1485–1494CrossRefPubMed

10.

Nojiri T, Hosoda H, Kimura T, Miura K, Ishikane S, Tokudome T, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K (2015) Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury. Cancer Chemother Pharmacol 75:123–129CrossRefPubMed

11.

Ventura GJ, Reading CL, Hester JP, Vadhan-Raj S (1990) Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration. Acta Haematol 84:175–181CrossRefPubMed

12.

Mehta HM, Malandra M, Corey SJ (2015) G-CSF and GM-CSF in neutropenia. J Immunol 195:1341–1349CrossRefPubMed

13.

Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404CrossRefPubMedPubMedCentral

14.

Bohlius J, Reiser M, Schwarzer G, Engert A (2003) Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 122:413–423CrossRefPubMed

15.

Nishida M, Fujimoto S, Toiyama K, Sato H, Hamaoka K (2004) Effect of hematopoietic cytokines on renal function in cisplatin-induced ARF in mice. Biochem Biophys Res Commun 324:341–347CrossRefPubMed

16.

Iwasaki M, Adachi Y, Minamino K, Suzuki Y, Zhang Y, Okigaki M, Nakano K, Koike Y, Wang J, Mukaide H, Taketani S, Mori Y, Takahashi H, Iwasaka T, Ikehara S (2005) Mobilization of bone marrow cells by G-CSF rescues mice from cisplatin-induced renal failure, and M-CSF enhances the effects of G-CSF. J Am Soc Nephrol 16:658–666CrossRefPubMed

17.

Nojiri T, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, Inoue M, Okumura M (2012) Effect of low-dose human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer: a double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 143:488–494CrossRefPubMed

18.

Nojiri T, Inoue M, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, Okumura M (2012) Effects of low-dose human atrial natriuretic peptide for preventing post-operative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer. Eur J Cardiothorac Surg 41:1330–1334CrossRefPubMed

19.

Nojiri T, Inoue M, Maeda H, Takeuchi Y, Sawabata N, Shintani Y, Yamamoto K, Okumura M (2013) Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery. Eur J Cardiothorac Surg 44:98–103CrossRefPubMed

20.

Nojiri T, Hosoda H, Tokudome T, Miura K, Ishikane S, Otani K, Kishimoto I, Shintani Y, Inoue M, Kimura T, Sawabata N, Minami M, Nakagiri T, Funaki S, Takeuchi Y, Maeda H, Kidoya H, Kiyonari H, Shioi G, Arai Y, Hasegawa T, Takakura N, Hori M, Ohno Y, Miyazato M, Mochizuki N, Okumura M, Kangawa K (2015) Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells. Proc Natl Acad Sci USA 112:4086–4091CrossRefPubMedPubMedCentral

21.

Alderson MR, Tough TW, Ziegler SF, Grabstein KH (1991) Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 173:923–930CrossRefPubMed

22.

Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T (1990) Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783–836CrossRefPubMed

Titel: RETRACTED ARTICLE: Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia
verfasst von: Takashi Nojiri
Hiroshi Hosoda
Masahiro Zenitani
Takeshi Tokudome
Toru Kimura
Koichi Miura
Mikiya Miyazato
Meinoshin Okumura
Kenji Kangawa
Publikationsdatum: 10.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3075-x

Springer Medizin

RETRACTED ARTICLE: Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia